Novel antagonists of toll-like receptor 4 (TLR-4) are provided. More specifically, the novel antagonists of TLR-4 are derived from morphinan. Further, use of said morphinan derivatives in the treatment of diseases and/or disorders mediated by TLR-4, such as autoimmune diseases, inflammation disease and infectious diseases, is provided. Pharmaceutical compositions including said morphinan derivatives are also provided.
提供了新型Toll样受体4(TLR-4)拮抗剂。更具体地说,这些新型TLR-4拮抗剂源自
吗啡类化合物。此外,提供了利用这些
吗啡类衍
生物治疗由TLR-4介导的疾病和/或疾病的方法,如自身免疫疾病、炎症性疾病和传染病。还提供了包含这些
吗啡类衍
生物的药物组合物。